A new BRAF inhibitor breaks resistance barriers.
Trends Cancer
; 10(7): 576-578, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38866669
ABSTRACT
Approved BRAF inhibitors have shown limited clinical benefit due to recurrent disease progression. In a recent Cancer Discovery paper, Yaeger et al. show that a next-generation BRAF inhibitor, PF-07799933, has widespread therapeutic activity in experimental models and patients who were refractory to treatment with approved BRAF inhibitors.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Resistencia a Medicamentos Antineoplásicos
/
Proteínas Proto-Oncogênicas B-raf
/
Inibidores de Proteínas Quinases
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article